Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Retained Earnings (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Retained Earnings for 9 consecutive years, with $415000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings changed N/A to $415000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $415000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $415000.0 for FY2025, N/A changed from the prior year.
  • Retained Earnings for Q4 2025 was $415000.0 at Soleno Therapeutics, up from $360000.0 in the prior quarter.
  • The five-year high for Retained Earnings was $415000.0 in Q4 2025, with the low at -$500.7 million in Q2 2025.